Novartis’ Cosentyx (secukinumab) Receives the NMPA’s Approval for the Treatment of Pediatric Psoriasis in China
Novartis Presents Two-Year Data of Cosentyx (secukinumab) in P-III JUNIPERA Study for JPsA and ERA at ACR 2021
Shots:
- The approval is based on two P-III international studies that evaluate cosentyx in pediatric patients aged 6 to <18 yrs. with mod. to sev. PsO who are candidates for systemic therapy or phototherapy
- The results showed that the therapy is safe and effective for children and adults with PsO. Additionally, therapy has supported the 5yrs. sustained efficacy and safety data across several inflammatory conditions
- The company has filed for regulatory approval in the US and EU for cosentyx to treat JPsA and ERA & plans to expand the therapy to 10 indications over the next 10 yrs. The therapy is also approved in China for adults with moderate-to-severe PsO & ankylosing spondylitis
Click here to read full press release/ article | Ref: Novartis | Image: Clinical Trials Arena